Post-approval studies (Phase 4)Study completedNCT00044187
What this trial is testing
The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
Who this might be right for
SchizophreniaPsychotic DisordersBipolar Disorder
Eli Lilly and Company 130